Arrowhead Pharmaceutials Announces the Publication of Two Back-to-back NEJM Manuscripts

Last Updated: Wednesday, 29-May-2024 22:00:00 EDT

Arrowhead Pharmaceuticals is proud to announce the publication of two back-to-back NEJM manuscripts in the mixed hyperlipidemia population with plozasiran (MUIR study with APOC3 target) and zodasiran (ARCHES2 study with ANGPTL3 target) following the EAS presentations by Drs. Ballantyne and Rosenson.

The press releases with manuscript information can be accessed here.